Clicky

NLS Pharmaceutics Ltd.(NLSP)

Description: NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of drug therapies to treat rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its two lead product candidates, include Quilience, for the treatment of excessive daytime sleepiness and cataplexy; and Nolazol, for the treatment of ADHD. NLS Pharmaceutics AG was founded in 2015 and is based in Stans, Switzerland.


Keywords: Biopharmaceutical Neurological Disorders Psychiatric Diagnosis Psychiatry Sleep Disorders Attention Deficit Hyperactivity Disorder Drug Therapies Amphetamine Narcolepsy Methylphenidate Adhd Childhood Psychiatric Disorders Cataplexy

Home Page: nlspharma.com

NLSP Technical Analysis

The Circle 6
Zurich, 8058
Switzerland
Phone: 41 44 512 21 50


Officers

Name Title
Mr. Alexander Zwyer M.B.A. Pres, CEO & Director
Mr. Chad C. Hellmann M.B.A. Chief Financial Officer
Mr. Eric Konofal M.D., Ph.D. Chief Scientific Officer
Dr. Christian C. Wenger Dr. iur., L.L.M., LL.M., Ph.D. Gen. Counsel
Ms. Sharon Keys Head of Regulatory Affairs
Dr. George Apostol M.D. Chief Medical Officer and Global Head of R&D

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 25.7772
Price-to-Sales TTM: 0
IPO Date: 2021-01-29
Fiscal Year End: December
Full Time Employees: 6
Back to stocks